ClinicalTrials.gg
CompletedNCT01490788Updated Sep 11, 2019Results posted

A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults.

A Phase 1 interventional study of Treatment A and Treatment B in Healthy, sponsored by Tonix Pharmaceuticals, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-11.

Sponsored by Tonix Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The trial is designed to assess the safety and tolerability of TNX-102 2.4 mg and to compare the bio-availability of TNX-102 2.4 mg and cyclobenzaprine 5 mg tablets under fasting or fed conditions.

Read the detailed description

Single-center, randomized, open-label, single-dose, three-way-crossover trial is designed to assess the safety and tolerability of TNX-102 2.4 mg (a dose based on the results of a previous Phase 2a, proof-of-concept study - VPI-CY-0001.1) and to compare the rate and extent of absorption of TNX-102 2.4 mg and cyclobenzaprine 5 mg tablets under fasting or fed conditions.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Tonix Pharmaceuticals, Inc. is the lead sponsor of 34 studies on the registry; 1 is open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 12 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Healthy adults

  • Male or female
  • Non-smoker
  • 18-55 years old
  • > 18.5 and \< 30.0
  • With medically acceptable form of (female only).

Exclusion Criteria:

  • Any abnormality or vital sign abnormalities
  • Any abnormal laboratory test
  • History of alcohol or drug abuse or dependence within 1 year and/or positive drug, cotinine, or alcohol tests
  • Use of any drug (within 30 days), supplement, or food (within 14 days) known to induce or inhibit hepatic drug metabolism prior to study medication
  • Positive pregnancy test, breastfeeding or lactating
  • Use of medication other than hormonal contraceptives or topical products, including OTC, natural health products, MAO inhibitors
  • Participation in an study within 30 days prior to dosing
  • Donation of plasma (within 7 days), or donation or loss of blood of 50-499 mL (within 30 days), or of > 499 mL (within 56 days) prior to dosing.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Treatment A

    1 x TNX-102 2.4 mg gelcap under fasting conditions

    Drug: Treatment A

  • Experimental
    Treatment B

    1 x cyclobenzaprine 5 mg immediate release (IR) tablet under fasting conditions

    Drug: Treatment B

  • Active comparator
    Treatment C

    1 x TNX-102 2.4 mg gelcap under fed conditions

    Drug: Treatment C

Interventions

  • TNX-102 2.4 mg - 1 gelcap once under fasting conditions.

    Also known as: cyclobenzaprine HCl

  • Cyclobenzaprine 5 mg, 1 tablet once under fasting conditions

    Also known as: cyclobenzaprine HCl

  • TNX-102 2.4 mg, 1 gelcap once given under fed conditions.

    Also known as: cyclobenzaprine HCl

06

What researchers measure

Primary outcomes

  1. Mean Plasma Concentration (AUC) of Cyclobenzaprine

    Blood samples were collected pre-dose, 30 min, 1, 1.5, 2, 2.5, 3, 3.33, 3.67, 4, 4.67, 5, 5.5, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose for each treatment period.

    Time frame: 0 to 96 hours

  2. Incidences of Adverse Events

    Every adverse events occurring during the study period will be reported.

    Time frame: Continuously until the end (day 5) of each study period + 8-10 days after end of last period (total duration: about 1 month)

07

Results

Posted Nov 2, 2018

Participant flow

Participant flow — Overall Study
MilestoneTreatment A First, Then B, Then CTreatment A First, Then C, Then BTreatment B First, Then A, Then CTreatment B First, Then C, Then ATreatment C First, Then A, Then BTreatment C First, Then B, Then A
Started555555
Completed455555
Not completed100000

Outcome measures

PrimaryMean Plasma Concentration (AUC) of Cyclobenzaprine

Blood samples were collected pre-dose, 30 min, 1, 1.5, 2, 2.5, 3, 3.33, 3.67, 4, 4.67, 5, 5.5, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose for each treatment period.

Time frame:
0 to 96 hours
Reported as:
Mean · pg.hr/mL
Mean Plasma Concentration (AUC) of Cyclobenzaprine
pg.hr/mLTreatment ATreatment BTreatment C
Mean Plasma Concentration (AUC) of Cyclobenzaprine47,074.19 (30288.11 to 63860.27)94,874.26 (60588.45 to 129160.07)50,263.16 (30725.75 to 69800.57)
PrimaryIncidences of Adverse Events

Every adverse events occurring during the study period will be reported.

Time frame:
Continuously until the end (day 5) of each study period + 8-10 days after end of last period (total duration: about 1 month)
Reported as:
Count of participants · Participants
Incidences of Adverse Events
ParticipantsTreatment ATreatment BTreatment C
Subjects with Treatment-Emergent Adverse Events141510
Subjects with Serious Adverse Events000
Subjects discontinued due to adverse event000

Adverse events

Collected over 2 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A0/30 (0%)0/30 (0%)14/30 (46.7%)
Treatment B0/30 (0%)0/30 (0%)15/30 (50%)
Treatment C0/30 (0%)0/30 (0%)10/30 (33.3%)
Most frequent other events
Showing 10 of 29
Most frequent other events
EventTreatment ATreatment BTreatment C
SomnolenceNervous system disorders3/3011/302/30
ConstipationGastrointestinal disorders3/301/301/30
Abdominal distensionGastrointestinal disorders2/300/301/30
Blood Pressure increasedInvestigations2/301/301/30
catheter site painGeneral disorders1/300/302/30
PalpitationsCardiac disorders1/300/300/30
Ear DiscomfortEar and labyrinth disorders0/300/301/30
PhotophobiaEye disorders0/301/300/30
Abdominal PainGastrointestinal disorders1/300/300/30
DiarrhoeaGastrointestinal disorders0/300/301/30

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)All Study Participants
<=18 years0
Between 18 and 65 years30
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female8
Male22
Region of Enrollment
Region of Enrollment(participants)All Study Participants
Canada30
08

Study locations

1 site
  • PharmaNet, Inc.
    Québec City, Quebec G1P 0A2, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2018, 6 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2011
First posted
Dec 13, 2011
Start
Nov 18, 2011
Primary completionActual
Dec 30, 2011
CompletionActual
Dec 30, 2011
Results first posted
Nov 2, 2018
Last update
Sep 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01490788
Responsible party
Sponsor
First posted
Dec 13, 2011
Start date
Nov 18, 2011
Primary completion
Dec 30, 2011
Completion
Dec 30, 2011
Results posted
Nov 2, 2018
Last update
Sep 11, 2019

Study contacts

Denis Audet, MD
principal investigator · PharmaNet

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclobenzaprine

Start the discussion